antibiotic resistance
Torus Biosystems Completes $25M Series A Financing Round
The funding round was led by Northpond Ventures, and Northpond's director Adam Wieschhaus will join Torus' board of directors.
The company plans on launching two new iterations of its Pheno platforms this year, and one in late 2023.
The company is working to transition its instruments sold in the US from COVID-19 testing to sepsis testing and increase its installed base.
Accelerate Diagnostics Q1 Revenues Climb 9 Percent, Miss Analyst Estimates
The company said that it added two contracted Pheno instruments and brought 12 instruments live in the US in the recently completed quarter.
The firm also recently validated its instrument-agnostic technology's ability to detect up to 20 targets per qPCR well using high-definition PCR.
Mar 15, 2021
Roche to Acquire GenMark Diagnostics for $1.8B
Jan 13, 2021
OpGen Preliminary Q4 Revenue Climbs 63 Percent
Sep 30, 2020